Price$28.70+0.10 (+0.37%)
01:30 PM07:45 PM
News · 26 weeks59-56%
2026-01-182026-07-12
Mix2190d
- SEC Filings12(57%)
- Other7(33%)
- Analyst2(10%)
Latest news
25 items- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 4,207 million in the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the w
- PRGenmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaTEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE® FL-1 trial, fixed-duration TEPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete response Genmab A/S (NASDAQ:GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people wi
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PatientsFindings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting Epcoritamab in combination with R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress Genmab A/S (NASDAQ:GMAB) today announced new data from a
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTTruist initiated coverage on Genmab with a new price targetTruist initiated coverage of Genmab with a rating of Buy and set a new price target of $40.00
- PRGenmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 CongressTwenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of the safety and efficacy of Genmab's investigational late-stage medicines, rinatabart sesutecan and petosemtamab Data evaluating epcoritamab will demonstrate outcomes across monotherapy, combination regimens and fixed-duration use, including outpatient administration and use in earlier lines of treatment Genmab A/S (NASDAQ:GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a su
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Genmab A/SSCHEDULE 13G/A - GENMAB A/S (0001434265) (Subject)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026, Orbis Investment Management Limited controlled the voting rights to 3,166,357 shares in Genmab A/S, which amounts to 5.08% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with c
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTGenmab upgraded by GoldmanGoldman upgraded Genmab from Neutral to Buy
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people
GMAB FAQ
7 questionsWhat does Genmab A/S do?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers...Where does GMAB stock trade?
Genmab A/S (GMAB) is listed on NASDAQ.What sector and industry is GMAB in?
Genmab A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genmab A/S go public?
Genmab A/S (GMAB) completed its IPO in 2019.What are analysts saying about GMAB?
Genmab A/S has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $4000.00 price target on 2026-05-27. Recent price targets range from $3200.00 to $4300.00.What companies are similar to GMAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GMAB side-by-side with any of them on Quantisnow.How can I track GMAB on Quantisnow?
Quantisnow aggregates Genmab A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMAB to receive live email and push alerts on every new disclosure.